Karyopharm Therapeutics Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
228
- Stock Symbol
-
KPTIQ
- Investments
-
1
- Share Price
-
$0.03
- (As of Thursday Closing)
Karyopharm Therapeutics General Information
Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Contact Information
Website
www.karyopharm.comCorporate Office
- 85 Wells Avenue
- Suite 210
- Newton, MA 02459-3298
- United States
Corporate Office
- 85 Wells Avenue
- Suite 210
- Newton, MA 02459-3298
- United States
Karyopharm Therapeutics Timeline
Karyopharm Therapeutics Stock Performance
As of 19-Nov-2026, Karyopharm Therapeutics’s stock price is $0.03. Its current market cap is $769K with 22.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.03 | $0.04 | $769K | 22.7M | 8.67M | -$13.04 |
Karyopharm Therapeutics Financials Summary
As of 30-Jun-2026, Karyopharm Therapeutics has a trailing 12-month revenue of $147M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 361,441 | 276,040 | 146,077 | 68,322 |
| Revenue | 146,621 | 146,067 | 145,237 | 146,033 |
| EBITDA | (177,692) | (152,624) | (46,003) | (129,366) |
| Net Income | (224,740) | (196,039) | (76,422) | (143,099) |
| Total Assets | 111,317 | 108,416 | 164,418 | 240,438 |
| Total Debt | 256,192 | 233,607 | 194,524 | 177,016 |
Karyopharm Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Karyopharm Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Karyopharm Therapeutics Comparisons
Industry
Financing
Details
Karyopharm Therapeutics Competitors (60)
One of Karyopharm Therapeutics’s 60 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Aprea Therapeutics | Formerly VC-backed | Doylestown, PA | ||||
| SpringWorks Therapeutics | Formerly VC-backed | Stamford, CT | ||||
| Rigel Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Evotec | Formerly PE-Backed | Hamburg, Germany |
Karyopharm Therapeutics Patents
Karyopharm Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024168062-A1 | Selinexor and analogs for use in the treament of endometrial cancer in patients with wild-type tp53 gene | Inactive | 07-Feb-2023 | ||
| WO-2024102477-A1 | Crystalline forms of eltanexor and process for preparing same | Inactive | 11-Nov-2022 | ||
| AU-2022276509-A1 | Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms | Pending | 20-May-2021 | ||
| CA-3219525-A1 | Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms | Pending | 20-May-2021 | ||
| EP-4341253-A1 | Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms | Pending | 20-May-2021 | C07D403/06 |
Karyopharm Therapeutics Signals
Karyopharm Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Karyopharm Therapeutics Investments (1)
Karyopharm Therapeutics’s most recent deal was a Corporate Asset Purchase with Neumedicines (HemaMax, an Investigational Interleukin 12 (IL-12) and Certain Assets) for . The deal was made on 22-Jul-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neumedicines (HemaMax, an Investigational Interleukin 12 (IL-12) and Certain Assets) | 22-Jul-2021 | Corporate Asset Purchase | Buildings and Property |
Karyopharm Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.68 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Karyopharm Therapeutics FAQs
-
When was Karyopharm Therapeutics founded?
Karyopharm Therapeutics was founded in 2008.
-
Where is Karyopharm Therapeutics headquartered?
Karyopharm Therapeutics is headquartered in Newton, MA.
-
What is the size of Karyopharm Therapeutics?
Karyopharm Therapeutics has 228 total employees.
-
What industry is Karyopharm Therapeutics in?
Karyopharm Therapeutics’s primary industry is Drug Discovery.
-
Is Karyopharm Therapeutics a private or public company?
Karyopharm Therapeutics is a Public company.
-
What is Karyopharm Therapeutics’s stock symbol?
The ticker symbol for Karyopharm Therapeutics is KPTIQ.
-
What is the current stock price of Karyopharm Therapeutics?
As of 19-Nov-2026 the stock price of Karyopharm Therapeutics is $0.03.
-
What is the current market cap of Karyopharm Therapeutics?
The current market capitalization of Karyopharm Therapeutics is $769K.
-
What is Karyopharm Therapeutics’s current revenue?
The trailing twelve month revenue for Karyopharm Therapeutics is $147M.
-
Who are Karyopharm Therapeutics’s competitors?
Astellas Pharma, Aprea Therapeutics, SpringWorks Therapeutics, Rigel Pharmaceuticals, and Evotec are some of the 60 competitors of Karyopharm Therapeutics.
-
What is Karyopharm Therapeutics’s annual earnings per share (EPS)?
Karyopharm Therapeutics’s EPS for 12 months was -$13.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process